Champions Oncology was founded in 2007 and is headquartered in Hackensack, US
Key People at Champions Oncology
Joel Ackerman
CEO
Ronnie Morris
President
Scott Tobin
Director
Misti Ushio
Involved
Champions Oncology Office Locations
Champions Oncology has offices in Hackensack, Baltimore and London
Hackensack, US (HQ)
307 1 University Plaza Dr
London, GB
2 Royal College St
Baltimore, US
602 855 N Wolfe St
Champions Oncology Data and Metrics
Champions Oncology Financial Metrics
Champions Oncology's revenue was reported to be $11.2 m in FY, 2016 which is a 26% increase from the previous period.
USD
Revenue (FY, 2016) | 11.2 m |
Revenue growth (FY, 2015 - FY, 2016), % | 26% |
Net income (FY, 2016) | (10.4 m) |
EBIT (FY, 2016) | (10.3 m) |
Market capitalization (21-Jul-2017) | 29 m |
Cash (31-Jan-2017) | 3.5 m |
Champions Oncology's current market capitalization is $29 m.
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 11.6 m | 8.9 m | 11.2 m |
Revenue growth, % | (23%) | 26% | |
Sales and marketing expense | 3.4 m | ||
R&D expense | 4.2 m | ||
General and administrative expense | 5.2 m | ||
Operating expense total | 17.8 m | 22.1 m | 21.5 m |
EBIT | (6.3 m) | (13.2 m) | (10.3 m) |
EBIT margin, % | (54%) | (149%) | (92%) |
Net Income | (7.4 m) | (13.1 m) | (10.4 m) |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 5.9 m | 9.4 m | |
Accounts Receivable | 1.3 m | 1.1 m | 1.3 m |
Inventories | 383 k | 346 k | 443 k |
Current Assets | 7.6 m | 10.8 m | 4.3 m |
PP&E | 434 k | 452 k | 618 k |
Goodwill | 669 k | 669 k | 669 k |
Total Assets | 8.9 m | 12 m | 5.8 m |
Accounts Payable | 981 k | 1.4 m | 1.9 m |
Current Liabilities | 3.7 m | 3.8 m | 5.3 m |
Total Liabilities | 5.5 m | ||
Additional Paid-in Capital | 43.3 m | 61.2 m | 63.9 m |
Retained Earnings | (38.9 m) | (52 m) | (62.5 m) |
Total Equity | 3.2 m | 8.1 m | 238 k |
Financial Leverage | 2.8 x | 1.5 x | 24.3 x |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 3.1 m | 575 k | 182 k | 6.8 m | 4.2 m | 3.3 m | 4.5 m | 4.3 m | 3.5 m |
Accounts Receivable | 925 k | 1.1 m | 1.1 m | 1.5 m | 1.9 m | 2.1 m | 1.6 m | 1.9 m | 2 m |
Current Assets | 4.4 m | 2.1 m | 1.5 m | 8.6 m | 6.3 m | 5.8 m | 6.4 m | 6.7 m | 6.1 m |
PP&E | 411 k | 395 k | 469 k | 445 k | 420 k | 514 k | 590 k | 561 k | 672 k |
Goodwill | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k |
Total Assets | 5.7 m | 3.3 m | 2.8 m | 9.8 m | 7.6 m | 7.1 m | 7.8 m | 8 m | 7.5 m |
Accounts Payable | 1.3 m | 1.6 m | 1.4 m | 1.4 m | 1.3 m | 1.5 m | 1.5 m | 1.2 m | 1.3 m |
Current Liabilities | 3.4 m | 3.9 m | 6.3 m | 3.8 m | 3.3 m | 4.6 m | 4.4 m | 4.6 m | 5.3 m |
Additional Paid-in Capital | 44.1 m | 44.9 m | 45.4 m | 62.1 m | 62.8 m | 63.4 m | 69.4 m | 70 m | 70.2 m |
Retained Earnings | (42.4 m) | (45.6 m) | (48.4 m) | (54.9 m) | (57.5 m) | (59.9 m) | (65 m) | (65.5 m) | (66.9 m) |
Total Equity | 439 k | 5.9 m | 4.1 m | 2.3 m | 3.2 m | 3.2 m | 2 m | ||
Financial Leverage | 12.9 x | 1.7 x | 1.8 x | 3.2 x | 2.5 x | 2.5 x | 3.7 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | (7.4 m) | (13.1 m) | (10.4 m) |
Depreciation and Amortization | 213 k | 214 k | 156 k |
Accounts Receivable | (825 k) | 265 k | (282 k) |
Accounts Payable | (223 k) | 433 k | 482 k |
Cash From Operating Activities | (3.4 m) | (9.6 m) | (6.5 m) |
Purchases of PP&E | (234 k) | (119 k) | (322 k) |
Cash From Investing Activities | (234 k) | (114 k) | (322 k) |
Cash From Financing Activities | 21 k | 13.2 m | 2 k |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Accounts Receivable | 925 k | 1.1 m | 1.1 m | 1.5 m | 1.9 m | 2.1 m | 1.6 m | 1.9 m | 2 m |
Accounts Payable | 1.3 m | 1.6 m | 1.4 m | 1.4 m | 1.3 m | 1.5 m | 1.5 m | 1.2 m | 1.3 m |
| Y, 2017 | |
|---|---|
Financial Leverage | 3.7 x |
